Aug 25, 2009 - APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. FDA to market penicillin G potassium for Injection, USP, in two dosage strengths.
The details can be read here.
No comments:
Post a Comment